Exeliom Biosciences’ Post

Small cell lung cancer (SCLC) stands as a formidable and aggressive subtype of lung cancer, notorious for its rapid growth and propensity to metastasize early. Accounting for nearly 15% of all lung cancer cases, SCLC is characterized by its quick progression, often spreading to distant organs by the time of diagnosis. This cancer type’s aggressive nature requires clinical research to identify potential treatment modalities for patients with the disease. ASTRIDE is a Phase 3 clinical trial for the treatment of extensive stage SCLC. For Additional Information: https://lnkd.in/e42_UQ6P Fosun Pharma USA Inc. #lungcancer #SCLC The Balancing Act Lifetime Television#clincialtrials Payman Darouian Stan Lechpammer, MD, Ph.D. Brian Fiske George Eliades

For patients with advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, the estimated five-year survival rate is eight percent.    This is why at Johnson & Johnson Innovative Medicine, we are working tirelessly to redefine care for patients with lung cancer and advance treatments that can be used in earlier lines of therapy with the goal of extending survival.   Today, I’m pleased to share the U.S. FDA has granted full approval for our targeted therapy in combination with chemotherapy for first-line treatment of patients with advanced or metastatic NSCLC with EGFR exon 20 insertion mutations.   Learn more about our commitment to advancing the science and treatment of lung cancer: https://bit.ly/3v0fDQs   #MyCompany #LungCancer #NSCLC

This #BladderCancerAwarenessMonth let’s shine a light on immunotherapy offering hope to patients. The JAVELIN study presented by Powles et al. underscores the efficacy of our EpiSwitch® platform in predicting survival benefit for bladder cancer patients (#ESMO22). Notably, Keytruda, Opdivo, and Bavencio have all received FDA approval as immunotherapies for #bladdercancer. CiRT plays a pivotal role in identifying responders to these medications, a crucial step given the current lack of readily available biomarkers and molecular profiling for this cancer type. As we shift the paradigm of novel diagnostic innovation, let's raise awareness about the transformative potential of #immunotherapy in reshaping the landscape of bladder cancer treatment. #BladderCancerAwareness

NEW: Highlights from #SABCS2023: #novelagents and insights on #HER2 dynamics in #breastcancer 🇺🇸 🎥 Kevin Kalinsky, MD, MS, from the Winship Cancer Institute of Emory University, discusses exciting posters presented during the spotlight session at the San Antonio Breast Cancer Symposium (SABCS) 2023 💡The main focus is on new agents, including two #bispecificantibodies and a TROP-2 #antibodydrugconjugate (ADC) 💡A real-world analysis, RELIEVE, underscores the importance of #HER2 dynamics, revealing potential differences in outcomes for patients with #HER2-low #primarytumors and #metastatic tumors 💡The discussion emphasizes considerations about #toxicities, responses, and the optimal measurement of targets, questioning whether #targetedtherapies induce bystander effects that render assays less critical Take a look 👉 https://lnkd.in/ethirU9d Check out our #SABCS page for all the latest coverage 👉 https://lnkd.in/eYrYkh5C #SABCS23 #BreastCancer #BCsm #breastcancerawareness  American Association for Cancer Research

Exciting news for early-stage breast cancer patients! A new Phase 3 clinical trial (CAMBRIA 1) is exploring the use of camizestrant as an extended adjuvant therapy. This could potentially benefit patients with ER+/HER2- tumors and an intermediate or high risk of recurrence. What makes CAMBRIA 1 interesting? • Extended adjuvant therapy: The trial investigates the effectiveness of continued treatment beyond the standard endocrine therapy period. • Targeting ER+ cancers: The research focuses on a specific type of breast cancer that is estrogen receptor positive (ER+). Read More: This poster session abstract from the American Association for Cancer Research (AACR) delves deeper into the study design. https://lnkd.in/d_bcDbKd #BreastCancer #ClinicalTrials #ERPositiveCancer #AACR #TalentInfluencersLeaderboard #FortreaAlwaysOn #Fortrea

Curious about how the Onco-PDO® test works? Check out our infographic to see the step-by-step workflow of this revolutionary cancer treatment approach! Here's a brief overview: Tumor cells are cultured into mini-organs in a 3D structure, known as Patient-Derived Organoids (PDOs). The drugs selected by physicians are then tested on the patient's individual mini-organs (PDOs) in the lab. Each treatment's response is analyzed, and a report is delivered within a clinically relevant timeframe, allowing doctors to make more informed decisions for personalized cancer treatment. Contact us to learn more about the Onco-PDO® test. #PrecisionOncology #Livingsciences #cancertreatment #CancerCare #OncoPDO #PersonalizedMedicine #InnovativeTreatment #BetterOutcomes Follow us on Facebook at https://lnkd.in/gtZqUqGb and Instagram at https://lnkd.in/gKJyHuvh to gain access to our novel approach to personalizing cancer; the Onco-PDO® test that will reshape the landscape of oncology.

Exciting news for early-stage breast cancer patients! A new Phase 3 clinical trial (CAMBRIA 1) is exploring the use of camizestrant as an extended adjuvant therapy. This could potentially benefit patients with ER+/HER2- tumors and an intermediate or high risk of recurrence. What makes CAMBRIA 1 interesting? • Extended adjuvant therapy: The trial investigates the effectiveness of continued treatment beyond the standard endocrine therapy period. • Targeting ER+ cancers: The research focuses on a specific type of breast cancer that is estrogen receptor positive (ER+). Read More: This poster session abstract from the American Association for Cancer Research (AACR) delves deeper into the study design. https://lnkd.in/gcWz-Cy3 #BreastCancer #ClinicalTrials #ERPositiveCancer #AACR

Exciting news for early-stage breast cancer patients! A new Phase 3 clinical trial (CAMBRIA 1) is exploring the use of camizestrant as an extended adjuvant therapy. This could potentially benefit patients with ER+/HER2- tumors and an intermediate or high risk of recurrence. What makes CAMBRIA 1 interesting? • Extended adjuvant therapy: The trial investigates the effectiveness of continued treatment beyond the standard endocrine therapy period. • Targeting ER+ cancers: The research focuses on a specific type of breast cancer that is estrogen receptor positive (ER+). Read More: This poster session abstract from the American Association for Cancer Research (AACR) delves deeper into the study design. https://lnkd.in/gAnjFGtq #BreastCancer #ClinicalTrials #ERPositiveCancer #AACR

Exciting news for early-stage breast cancer patients! A new Phase 3 clinical trial (CAMBRIA 1) is exploring the use of camizestrant as an extended adjuvant therapy. This could potentially benefit patients with ER+/HER2- tumors and an intermediate or high risk of recurrence. What makes CAMBRIA 1 interesting? • Extended adjuvant therapy: The trial investigates the effectiveness of continued treatment beyond the standard endocrine therapy period. • Targeting ER+ cancers: The research focuses on a specific type of breast cancer that is estrogen receptor positive (ER+). Read More: This poster session abstract from the American Association for Cancer Research (AACR) delves deeper into the study design. https://lnkd.in/diunJC-V #BreastCancer #ClinicalTrials #ERPositiveCancer #AACR

🌟 𝐄𝐱𝐜𝐢𝐭𝐢𝐧𝐠 𝐍𝐞𝐰𝐬 𝐢𝐧 𝐂𝐚𝐧𝐜𝐞𝐫 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡! 🌟 🔬 A new study by S. T. Diepstraten et al., published in Cancer Cell, reveals a promising therapy for TP53-mutant blood cancers, a clinical challenge in cancer treatment. 🔑 Key Points: ● BH3-mimetic drugs induce apoptosis in cancer cells, with p53 enhancing this effect. ● Activation of the STING pathway triggers p53-independent apoptosis in blood cancers. ● Combining STING agonists with BH3-mimetic drugs efficiently kills TP53-mutant cancer cells. ☛ This innovative approach offers hope for improving treatment outcomes in challenging TP53-mutant blood cancers. Stay updated on the latest advancements in cancer research! 🎗️💡 #CancerResearch #BloodCancer #MedicalBreakthroughs